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abstract
CONTEXT: The diagnosis of primary melanoma is easily confirmed
after histological analysis of the lesion, whereas it is rarely diagnosed
when the patient even has distant metastases.
DESIGN: Case report
CASE REPORT: Malignant melanoma is responsible for about 1% of
all deaths caused by cancer in the USA and only 3% of all malig-
nant skin diseases. Malignant melanoma is a rare disease, although
it corresponds to 65% of all deaths caused by skin cancer. The liver
and spleen are rarely the first sites of melanoma metastases. This
paper reports on the clinical picture of a patient with fatal malignant
melanoma and hepatic and spleen metastases. As this was an un-
usual presentation, the melanoma diagnosis could only be made
after pathological analysis of the skin and hepatic lesions.
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INTRODUCTION
The diagnosis of primary melanoma is easily con-
firmed after histological analysis of the lesion, whereas
it is rarely diagnosed when the patient even has distant
metastases (8% of cases).1 This is probably due to the
fact that the time between diagnosis of the primary le-
sion and the appearance of metastases is very long.
Klaase et al. (1990) found an average time of 3 years for
melanoma and metastases, among 30 patients studied.2
Malignant melanoma represents about 1% of all
cancers and deaths in the USA but only 3% of all malig-
nant skin diseases, although it is responsible for 65% of
deaths caused by skin cancer. It shows a progressive in-
crease in incidence with age, with the patients being
mainly between 30 and 60 years old. Melanoma is more
common among the white races. The skin pigment has a
protective function in colored people, especially the black
and yellow races. The most important cause of this can-
cer seems to be solar exposure.3 The primary lesions are
located in: limbs (22%), trunk (40%), head and neck (15%),
and 16% in unknown sites (4). The most common sites
of metastases found in the autopsy are: skin and subcu-
taneous tissue (75%), lung (70%), liver (68%), small in-
testine (58%), pancreas (53%), heart (49%), brain (39%)
and spleen (36%).5 The average survival period for pa-
tients with non-visceral metastases is 7.2 months, but it
falls to 2.4 months when liver metastases are consid-
ered, whether associated with other organs or not.1
CASE REPORT
A 60-year-old white Brazilian male was hospi-
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talized for investigation with a two month history of
abdominal pain, altered intestinal function, lack of
appetite and asthenia, accompanied by chills and night
fever. The patient reported an unquantifiable weight
loss and he had been smoking twenty cigarettes a day
for the last 30 years.
Physical examination revealed that he had a
regular general state, and he was anemic but not jaun-
diced or febrile. Nodular lesions were observed over
the whole body of approximately 1cm diameter, fiber-
elastic in nature, without infiltration into deeper tis-
sues, covered only by skin of normal aspect. There was
one nodule of approximately 2 cm diameter, in the
posterior face of the left outer ear that was hardened,
ulcerated and associated with nearby angiomas. The
liver was observed to be 12 cm below the right costal
margin, hardened on its costal edge, nodular, painful,
and the Traube space was massive.
 Pertinent laboratory findings are shown in Table
1. Biochemical assays showed normal bilirubin, as-
partate aminotransaminase (AST) greater than alanine
aminotransaminase (ALT), low serum albumin, altered
prothrombin activity (PA), high cholestatic enzymes
(alkaline phosphatase, AP; and gamma glutamyl trans-
ferase, gGT), and very high lactic dehydrogenase
(LDH).
Oral endoscopy revealed 3 thin varicose cords
and scarring from a duodenal ulcer. Sonography of the
abdomen showed heterogeneous hepatomegaly and
splenomegaly with multiple images suggestive of
nodular metastatic lesions in the liver and spleen.
There was a nodular image suggestive of peripancreatic
ganglia and a left kidney cyst. Computed tomography
of the abdomen confirmed the presence of hepatic and
spleen nodules, suggestive of metastatic neoplasm
(Figure 1). Colonoscopy showed hypertonic diverticu-
lar disease. Other exams such as bone scintigraphy
with 99mTc-methylene diphosphonate (99mTc-MDP)
showed heterogeneous distribution of the
radioindicator in the ribs, and computed tomography
of the thorax and bronchoscopy did not suggest any
malignant lesions. Biopsies (skin and liver) revealed
malignant melanoma in the lesion of the left outer
ear and melanotic metastases in the subcutaneous
tissues and hepatic nodules (Figure 2).
The patient’s general state declined rapidly with
weight loss, asthenia, painful abdominal distention
radiating to the back, ascites, pleural spillage to the
right, bilateral edema involving the lower extremities,
dyspnea and torpor. After 22 days in hospital, he de-
veloped acute anemia and urinary hemorrhage. The
final laboratory examinations are shown in Table 1. At
this time the patient developed persistent acidosis (pH
= 7.25, bicarbonate = 12.1 mmol/L and BE = -12.8)
which did not respond to the treatment. Death oc-
curred on the 24th day.
DISCUSSION
The initial clinical diagnosis was of colorectal
cancer with hepatic and splenic metastases, because
of the changes in intestinal function and the fact that
the large intestine is an usual primary source of liver
metastases.6 The primary cancer situated on the left
outer ear did not have the typical macroscopic char-
acteristics of malignant melanoma. Therefore, the fi-
nal diagnosis was only conclusive after histological
analysis of the lesion.
Despite the low frequency of metastatic tumors
in the spleen (4%), these are more frequently encoun-
tered in autopsies of patients with melanoma (36%).5
The diagnosis of metastatic melanoma in the spleen
is rare, although this patient presented splenic me-
tastases at the time of diagnosis. Marked splenom-
egaly is not common, probably because the average
size of the nodules is 1.5 cm.5
The frequency with which the liver is observed
to be the initial site of melanoma metastases is ap-
proximately 4%. The initial clinical presentation in-
cludes weakness, anorexia, hepatomegaly and abnor-
Table 1 - Results of blood examinations at the
initial and in the terminal phases of
the patient with malignant melanoma
Examinations Entrance Terminal phase
Hb/Htc 11.2/33 6.4/19
White blood cells 12200 15500
Differential (leukocytes) 2/70/3/13/11 21/64/0/9/6
Platelets 336000 22700
AST/ALT 55/47 3152/554
AP/gGT 1156/477 1518/348
TB/CB 0.9/0.4 1.1/0.8
PA 57.7% 44.7%
Albumin 2.5 2.1
LDH 5724 12765
Na/K 136/3.9 128/6.0
Hematuria Negative 320,000
CEA Normal
AFP Normal
HbsAg Negative
HCV antibody Negative
Hb- hemoglobin (g/dl); Htc- hematocrit (%); Differential (metamyelocyte,
segmented neutrophil, eosinophil, lymphocyte, monocyte); AST- aspar-
tate aminotransaminase (nl: < 37 U/L) and ALT- alanine aminotransaminase
(nl: < 40 U/L); AP- alkaline phosphatase (nl: 50-250 U/L) and gGT-
gamma glutamyl transferase (nl: 11-43 U/L); TB- total bilirubin and CB-
conjugated bilirubin; PA- prothrombin activity; LDH- lactic dehydrogenase;
Na- sodium and K- potassium; Hematuria- red blood cells/ml of urine;
CEA- carcinoembryonic antigen; AFP- alpha fetus protein; HbsAg- hepa-
titis B surface antigen.
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mal liver function tests,5 which are common in any
chronic hepatic disease. The initial laboratory tests
(Table 1) showed our case to be chronic hepatic dis-
ease, with a cholestasis pattern. There was a signifi-
cant increase in LDH, suggesting tissue necrosis, which
could be described as tumoral invasion.
The initial investigation of abdominal tumor
metastases, as for melanoma, should be done using
sonography. Computed tomography and nuclear mag-
netic resonance should also be considered. Melanotic
liver metastases are poorly vascularized in hepatic
arteriography and small lesions may be easily missed.
Diagnostic explorations via radioscintigraphy, espe-
cially using 99mTc-DMP, produce both false negative and
false positive results and are thus not useful in the
initial phases of melanoma when there is no hepatic
lesion.7 Although the liver biochemical tests showed
hepatic alterations, the use of 99mTc-DMP did not ap-
pear to add any other conclusion. Hepatic biopsy is a
sensitive examination for the diagnosis of metastatic
melanoma and the chances of a positive result are
increased if the biopsy needle is directed into the le-
sion under ultrasound, computed tomography or peri-
toneoscopic guidance. Das Gupta and Brasfield (1964)
showed that the incidence of hepatic metastases at
necropsy is 68% and that the nodules are usually mul-
tiple, varying in size from 0.5 to 6.0cm diameter, pro-
voking hepatomegaly.5
Metastatic melanoma in the skin and/or subcu-
taneous tissue of the trunk and extremities is found
in 75% of patients at autopsy. These metastases re-
sult from either lymphatic or vascular dissemination.
Melanotic bone metastases are rare (2%) and difficult
to determine.5
The factors responsible for the death of our pa-
tient were probably hemorrhagic and metabolic com-
plications. The destruction of the hepatic parenchyma
by the tumor led to significant enzymatic alterations
(Table 1), characterized by the increase of AST, ALT
and LDH, the cholestatic pattern with high level of
gGT and AP, and low serum level of albumin and al-
tered PA. Jaundice usually indicates advanced hepatic
disease,5 which did not occur in our patient. However
the pattern of chronic hepatic disease also contrib-
uted to the death of our patient.
At the terminal phase, metabolic acidosis was
observed. This could be a consequence of increased
production of lactic acid due to inadequate periph-
eral tissue oxygenation or altered metabolic functions
such as insufficient capacity for hepatic clearance of
lactate caused by the replacement of normal liver mass
by tumor. It is suspected that these metastatic lesions
cause local hypermetabolism, thereby worsening he-
patic hypoxia and exacerbating lactic acidosis.8 Fur-
thermore, the development of ascites and gradual
edema of the lower extremities suggests retroperito-
neal or mesenteric metastases, which usually have a
very bad prognosis.5 The patient developed very pro-
nounced anemia due to hematuria exacerbated by low
platelets and altered PA. Another contribution to this
fatal evolution could have been the infection demon-
strated by the left-deviating leukocytosis.
A diagnosis of metastatic melanoma in the blad-
der can be made in almost all terminal patients with
hematuria and melanuria by means of cystoscopy.
However, this type of diagnosis is rarely of any practi-
cal importance. The main organs of the genitourinary
Figure 2 -  High magnification photomicrograph showing
metastatic melanoma in liver tissue. Large cells with
vesicular nuclei, prominent nucleoli and eosinophilic
cytoplasm (hematoxylin and eosin, 400X).
Figure 1 - Abdominal computed tomography, showing
widespread hypodense nodules in the hepatic and spleen
beds, corresponding to a metastatic neoplasm.
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tract that become involved are: kidney (45%), bladder
(18%) and prostate (3%).5 Hematuria was present in
this patient in the terminal stage of the disease and
the site of the lesion causing these symptoms was not
determined. A necropsy would have been of great di-
agnostic value for understanding this rapid and fatal
evolution. However the patient’s family did not au-
thorize this, and it was not performed.
The incidence of and mortality from melanoma
are increasing and no effective treatment for the dis-
seminated disease exists. Programs for prevention and
early detection of melanoma are therefore warranted.9
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resumo
CONTEXTO: O melanoma maligno é responsável por
aproximadamente 1% de todas as mortes causadas por câncer nos
EUA e apenas 3% de todas as doenças malignas cutâneas. Embora
considerada uma patologia rara, representa 65% de todos os óbitos
por câncer de pele. O fígado e o baço raramente são os primeiros
sítios de metástases de melanoma.
TIPO DE ESTUDO: Relato de caso.
RELATO DE CASO: Este artigo relata o quadro de um paciente
portador de melanoma maligno evoluindo para óbito com metástases
hepática e esplênica. Por ser uma apresentação atípica da doença,
o diagnóstico definitivo ocorreu somente após a análise
histopatológica das lesões de pele e do fígado.
PALAVRAS-CHAVE: Melanoma. Metástases hepática. Metástases
esplênica.
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